Skip to content

MDMA: all studies

Page 25 of 345: studies 241 to 250 of 3,446, newest first. Back to the MDMA overview

Research

Author Correction: MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial.

Nature Medicine November 1, 2024 Jennifer Mitchell, Marcela Ot’alora G., Bessel Van der Kolk et al. 4 citations

In the version of the article initially published, some members of the MAPP2 Study Collaborator Group were listed only in the Supplementary Information. Charlotte Harrison, Berra Yazar-Klosinski, Wael Garas, Darrick May, Cole Marta, Susan Walker, Elizabeth Nielson, Gregory Wells, Randall Brown, Revital Amiaz, Yair Wallach, Ray Worthy, Alia Lilienstein and Amy Emerson have now been added to the...

Psychedelic and MDMA-Related Adverse Effects-A Call for Action.

JAMA Health Forum November 1, 2024 Otto Simonsson, Matthew W. Johnson, Peter S. Hendricks 10 citations

This Viewpoint discusses the need to better understand potential risks associated with psychedelic and 3,4-methylenedioxymethamphetamine (MDMA) use to ensure safe and ethical practice and identifies 4 key research goals.

DOI: 10.1001/jamahealthforum.2024.3630 (opens in new tab) Psychedelic therapy Adverse effects Patient safety Preparation & integration

MDMA-assisted psychotherapy for PTSD in adolescents: rationale, potential, risks, and considerations.

European Child & Adolescent Psychiatry November 1, 2024 Samuli Kangaslampi, Josjan Zijlmans 18 citations

3,4-Methylenedioxymetamphetamine(MDMA)-assisted psychotherapy (MDMA-AP) is a proposed treatment for posttraumatic stress disorder (PTSD) that may be approved for adults soon. PTSD is also common among trauma-exposed adolescents, and current treatments leave much room for improvement. We present a rationale for considering MDMA-AP for treating PTSD among adolescents. Evidence suggests that as an...

Misrepresentation of MDMA in the United States, 1999-2023.

Drug and Alcohol Dependence November 1, 2024 Eric L Sevigny, Sylvia Thyssen, Earth Erowid et al. 5 citations

The misrepresentation of illicit drugs in unregulated markets increases the risk of adverse health events. This study analyzed drug checking data to compare represented, expected, and actual content of alleged MDMA samples, estimate trends in the quality of the MDMA supply, document the presence of adulterants, compare patterns of adulteration, and validate drug checking against law enforcement...

DOI: 10.1016/j.drugalcdep.2024.112467 (opens in new tab) Full text (opens in new tab) Safe supply Drug checking services MDMA Adulteration Harm reduction +2

Rapid Effects of MDMA Administration on Self-Reported Personality Traits and Affect State: A Randomized, Placebo-Controlled Trial in Healthy Adults.

Journal of Psychoactive Drugs October 23, 2024 Jessica L Maples-Keller, Courtland S Hyatt, Nathaniel L Phillips et al. 2 citations

3,4-methylenedioxymethamphetamine (MDMA) assisted therapy has been shown to be a safe and effective treatment for PTSD and emerging research suggests a change in personality traits may be a factor in treatment response. Most prior research on MDMA and personality has focused on cross-sectional comparisons of MDMA users and non-users; as such, well-controlled research assessing personality and...

DOI: 10.1080/02791072.2024.2420044 (opens in new tab) Full text (opens in new tab) Affect Clinical trial Psychedelic research Clinical psychology +3

Psicoterapias assistidas por MDMA no tratamento do estresse pós-traumático em adultos: uma revisão integrativa

Revista Sociedade Científica October 22, 2024 Manuela Bahia Almeida da Franca, Sandra Regina Mota Ortiz

O Transtorno do Estresse Pós-Traumático (TEPT) é caracterizado por um conjunto de sinais e sintomas associados a um profundo sofrimento psicológico após a vivência ou testemunha de um episódio traumático. Apesar de muito prevalente na população, a abordagem atual do transtorno possui importantes limitações, o que afeta de maneira significativa a qualidade de vida dos afetados. Diante desse...

5-HT2C receptors in the nucleus accumbens constrain the rewarding effects of MDMA.

bioRxiv : the preprint server for biology October 22, 2024 Matthew B Pomrenze, Sam Vaillancourt, Juliana S Salgado et al. 1 citation preprint

MDMA is a promising adjunct to psychotherapy and has well-known abuse liability, although less than other amphetamine analogs. While the reinforcing dopamine (DA)-releasing properties of MDMA are on par with methamphetamine (METH), MDMA is a far more potent serotonin (5-HT) releaser, via the 5-HT transporter (SERT). MDMA-mediated 5-HT release in a major reward center, the nucleus accumbens...

Consumo de MDMA e LSD por jovens e adolescentes: efeitos nocivos para saúde mental

Revista Eletrônica Acervo Saúde October 18, 2024 Lucas Siqueira Dos Santos, João Marcos Santos Oliveira, Layane Estefany Siqueira Dos Santos

Objetivo: Analisar as consequências para a saúde mental provocadas pelo consumo do Dietilamida do Ácido Lisérgico (LSD) e metilenodioximetanfetamina (MDMA) por jovens e adolescentes. Revisão bibliográfica: Este artigo promove uma discussão e análise acerca do consumo desenfreado de LSD e MDMA por jovens e adolescentes. O crescimento exponencial do mercado ilegal do tráfico de drogas e a criação...

Human Quest for Rapture and Ecstasy

HAL October 12, 2024 Philippe Rochat preprint

A universal aspect of human psychology is the quest and cultivation of rapture states, the need to stand outside oneself (ecstasy). The question is what may drive the human need to abandon and transcend a default mode of survival to cultivate altered states of consciousness? The idea is to approach this basic question in light of what arguably sets us apart in nature: human self-consciousness...